Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | SMO | Q99835 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | PNLIP | P16233 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280277 | 0.85 | NPC1 (0.71) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL4241801 | 0.82 | NPC1 (0.68) | NPC1RAB9AKCNK3KCNK9MAPT | |
| SCHEMBL4242085 | 0.82 | NPC1 (0.63) | NPC1RAB9AMAPTKMT2ATP53 | |
| SCHEMBL13689968 | 0.81 | NPC1 (0.66) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL4241238 | 0.81 | KMT2A (0.68) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL30369807 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL4254257 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL7553405 | 0.81 | KMT2A (0.61) | NPC1RAB9AKCNK3KCNK9MAPT | |
| SCHEMBL11322912 | 0.80 | RAB9A (0.73) | NPC1RAB9ASMOKCNK3KCNK9 | |
| SCHEMBL4244853 | 0.79 | KMT2A (0.65) | NPC1RAB9AKCNK3KCNK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009071519-A9 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009071519-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | NPC1 1641/4885RAB9A 2045/4885SMO 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.